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Migraine is a primary recurrent headache mani-
festing in attacks lasting 4-72 hours and aff ects 2-20% 
of world population. Women are more often aff ected, 
mostly during reproductive years. Th e migraine ef-
fects quality of life and has negative impact on work-
ing capability. 
Studies have showen that migraine is a common 
primary headache, but is not adequately diagnosed. 
Migraine is diagnosed in only 41% of women and 29% 
of men. Over 50% of patients with headacaches do not 
consult their medical doctors and among those who 
do, most of them do not go on check-ups. 
Also, migraine is an expensiv disease. A num-
ber of studies so far have evaluated the costs due to 
migraine. Th e costs can be divided into direct costs 
which include visits to the general practitioner and the 
emergency departments, costs of hospitalization and 
farmacotherapy. Indirect costs comprise 2/3 of total 
costs and include absence from work and costs due to 
reduced productivity. 
Th e exact mechanism of  patophysiology of mi-
graine hasn’t been established yet. Th e current state 
of knowledge in this fi eld suggests that a primary 
neuronal dysfunction leads to a sequence of changes 
intracranially and extracranially that account for mi-
graine, including the three phases of premonitory 
symptoms, aura, and headache. 
Central and peripheral sensitization are thought 
to play a role within individual migraine attacks and 
in the transformation of episodic migraine to chronic 
migraine. Sensitization refers to the process in which 
neurons become increasingly responsive to nociceptive 
and non-nociceptive stimulation: response thresholds 
decrease, response magnitude increases, receptive 
fi elds expand, and spontaneous neuronal activity de-
velops.
Th e once popular vascular theory of migraine is no 
longer considered viable in its original form. 
While the exact mechanism of serotonin action re-
mains obscure, there is evidence that a low serotonin 
state results in a defi cit in the serotonin descending 
pain inhibitory system, facilitating activation of the 
trigeminovascular nociceptive pathways in conjunc-
tion with cortical spreading depression.
Th e calcitonin gene-related peptide (CGRP) may 
also play a central role in migraine pathophysiology. 
CGRP may mediate trigeminovascular pain trans-
mission from intracranial vessels to the central ner-
vous system as well as neurogenic infl ammation. 
Elevated CGRP levels are normalized in patients 
with migraine following administration of the sero-
tonin 1b/1d receptor agonist sumatriptan [34], sug-
gesting that triptans may act to control migraine at 
least in part by reducing CGRP levels.
Pharmacologic modulation of CGRP activity of-
fers the promise of future treatment options for acute 
migraine attacks. 
Th e abortive (symptomatic) therapy of migraine 
ranges from the use of simple analgesics such as non-
steroidal antiinfl ammatory drugs (NSAIDs) or ac-
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etaminophen to triptans or the less commonly used 
dihydroergotamine. 
Th e serotonin 1b/1d agonists (triptans) are consid-
ered to be “specifi c” therapies for acute migraine since, 
in contrast to analgesics, they act at the pathophysi-
ologic mechanism of the headache. All of the triptans 
inhibit the release of vasoactive peptides, promote va-
soconstriction, and block pain pathways in the brain-
stem. Triptans inhibit transmission in the trigeminal 
nucleus caudalis, thereby blocking aff erent input to 
second order neurons; this eff ect is probably mediated 
by reducing the levels of calcitonin gene related pep-
tide (CGRP). Triptans may also activate 5-HT 1b/1d 
receptors in descending brainstem pain modulating 
pathways and thereby inhibit dural nociception.
Th e available triptans include sumatriptan, zol-
mitriptan, naratriptan, rizatriptan, almotriptan, elet-
riptan, and frovatriptan. In Croatia are available only 
three triptans (sumariptan, zolmitriptan and riza-
triptan). Sumatriptan can be given as a subcutaneous 
injection (usually admi-nistered by autoinjector in the 
thigh), as a nasal spray, or orally. Zolmitriptan is also 
available for both nasal and oral use. Th e others are 
available for oral use only. 
Prophylactic therapy is recommended when mi-
graine attacks are frequent, are long-lasting, acute 
therapy is not effi  cient or the side-eff ectc are serious. 
Several groups of prophylactic medications can be rec-
ommended. Beta blockers are the fi rst line for prophy-
laxis in patients who are normo- or hypertensive. 
Among antidepressants, the most effi  cient seems 
to be the tricyclic antidepressant amitriptyline, while 
selective inhibitors of serotonine reuptake (SSRI) 
seem to be less effi  cient. In the antiepileptic group, 
the most effi  cient is the valproat acid, gabapentine and 
topiramate.
Many studies pointed out the acupuncture to be 
eff ective in prophylaxis of migraine headache.
